{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:55:01Z","timestamp":1789664101887,"version":"4.0.1"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":459,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005407","name":"American Veterinary Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comparative pharmacokinetics and pharmacodynamics (PK\/PD) of apixaban and rivaroxaban have not been studied in dogs and the propensity of these drugs to cause hypercoagulability after discontinuation is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Compare the PK\/PD of clinical dosing regimens of PO apixaban and rivaroxaban administered repeatedly to healthy dogs and assess the effect of abrupt drug discontinuation on coagulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Six University-owned, purpose-bred, middle-aged, mixed-breed dogs (4 male, 2 female).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dogs were given apixaban or rivaroxaban PO at 0.5\u2009mg\/kg q12h for 7\u2009days with a 14-day washout period between drugs. Plasma drug concentrations were quantitated, and anticoagulant effects were measured using clotting times, calibrated anti-Xa bioactivity assays, and measurements of thrombin generation. The potential for rebound hypercoagulability was assessed by measuring D-dimers, thrombin-antithrombin (TAT) complexes, and antithrombin activity after drug discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma drug concentrations and anti-Xa bioactivities were closely correlated for both drugs, but drug concentrations varied considerably among dogs, despite consistent dose regimens. Thrombin generation variables were significantly correlated with the anti-Xa bioactivity of both drugs and no significant differences in the effects of apixaban and rivaroxaban on thrombin generation were observed. Drug discontinuation had no effect on D-dimer concentrations. The concentration of TAT complexes decreased after apixaban discontinuation and did not change after rivaroxaban discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Repeated PO administration of apixaban or rivaroxaban to healthy dogs produced comparable anticoagulant effects measured by inhibition of thrombin formation. Rebound hypercoagulability after drug discontinuation was not observed and weaning of these drugs in clinical patients might not be necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.17216","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T07:39:02Z","timestamp":1729150742000},"page":"3242-3254","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-094X","authenticated-orcid":false,"given":"Alex M.","family":"Lynch","sequence":"first","affiliation":[{"name":"NC State University Department of Clinical Sciences, , Raleigh, North Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Ruterbories","sequence":"additional","affiliation":[{"name":"NC State University Department of Clinical Sciences, , Raleigh, North Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Cornell University College of Veterinary Medicine Comparative Coagulation Laboratory, Department of Population Medicine and Diagnostic Sciences, , Ithaca, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fialkiewicz","sequence":"additional","affiliation":[{"name":"University of Georgia Department of Small Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-7898","authenticated-orcid":false,"given":"Mark G.","family":"Papich","sequence":"additional","affiliation":[{"name":"NC State University Department of Molecular Biomedical Sciences, , Raleigh, North Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-9013","authenticated-orcid":false,"given":"Marjory B.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Cornell University College of Veterinary Medicine Comparative Coagulation Laboratory, Department of Population Medicine and Diagnostic Sciences, , Ithaca, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-6987","authenticated-orcid":false,"given":"Robert","family":"Goggs","sequence":"additional","affiliation":[{"name":"Cornell University College of Veterinary Medicine Comparative Coagulation Laboratory, Department of Population Medicine and Diagnostic Sciences, , Ithaca, New York,","place":["USA"]},{"name":"Cornell University College of Veterinary Medicine Department of Clinical Sciences, , Ithaca, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2026020304133546800_jvim17216-bib-0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/vec.12797","article-title":"Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE): domain 1-defining populations at risk","volume":"29","author":"deLaforcade","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/vec.13204","article-title":"2022 update of the consensus on the rational use of antithrombotics and thrombolytics in veterinary critical care (CURATIVE) domain 1-defining populations at risk","volume":"32","author":"deLaforcade","year":"2022","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0003","doi-asserted-by":"crossref","first-page":"H818","DOI":"10.1152\/ajpheart.01197.2003","article-title":"Embolization itself stimulates thrombus propagation in pulmonary embolism","volume":"287","author":"Morris","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026020304133546800_jvim17216-bib-0004","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jsap.12185","article-title":"Comparison of computed tomography pulmonary angiography and point-of-care tests for pulmonary thromboembolism diagnosis in dogs","volume":"55","author":"Goggs","year":"2014","journal-title":"J Small Anim Pract"},{"key":"2026020304133546800_jvim17216-bib-0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2460\/javma.1998.213.02.220","article-title":"Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996)","volume":"213","author":"Palmer","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304133546800_jvim17216-bib-0006","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Jaspers Focks","year":"2016","journal-title":"BMJ"},{"key":"2026020304133546800_jvim17216-bib-0007","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jvsv.2021.04.016","article-title":"Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis","volume":"9","author":"Karathanos","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"2026020304133546800_jvim17216-bib-0008","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1939-1676.2010.0505.x","article-title":"Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs","volume":"24","author":"Helmond","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020304133546800_jvim17216-bib-0009","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11239-012-0751-5","article-title":"Thromboprophylaxis in major knee and hip replacement surgery: a review","volume":"34","author":"Eymin","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"2026020304133546800_jvim17216-bib-0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11239-019-01878-x","article-title":"Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism","volume":"48","author":"Giustozzi","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2026020304133546800_jvim17216-bib-0011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/vec.12795","article-title":"Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE): domain 3-defining antithrombotic protocols","volume":"29","author":"Blais","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0012","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jvc.2017.03.002","article-title":"Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study","volume":"19","author":"Borgarelli","year":"2017","journal-title":"J Vet Cardiol"},{"key":"2026020304133546800_jvim17216-bib-0013","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jvc.2021.05.010","article-title":"Phase I clinical trial of an antithrombotic drug protocol combining apixaban and clopidogrel in dogs","volume":"36","author":"Gagnon","year":"2021","journal-title":"J Vet Cardiol"},{"key":"2026020304133546800_jvim17216-bib-0014","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.702821","article-title":"Pharmacokinetics and biologic activity of Apixaban in healthy dogs","volume":"8","author":"Herrera","year":"2021","journal-title":"Front Vet Sci"},{"key":"2026020304133546800_jvim17216-bib-0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jvim.16359","article-title":"Stenting of the caudal aorta and aortic trifurcation for the treatment of thrombosis in 7 dogs","volume":"36","author":"Gavin","year":"2022","journal-title":"J Vet Intern Med"},{"key":"2026020304133546800_jvim17216-bib-0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jvc.2019.07.002","article-title":"Use of rivaroxaban for treatment of cranial vena cava syndrome secondary to transvenous pacemaker lead thrombosis in a dog","volume":"25","author":"Lozada Miranda","year":"2019","journal-title":"J Vet Cardiol"},{"key":"2026020304133546800_jvim17216-bib-0017","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vec.12480","article-title":"Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia","volume":"26","author":"Morassi","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0018","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12917-020-02632-9","article-title":"Successful management of portal vein thrombosis in a Yorkshire terrier with protein-losing enteropathy","volume":"16","author":"Sakamoto","year":"2020","journal-title":"BMC Vet Res"},{"key":"2026020304133546800_jvim17216-bib-0019","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/vec.13199","article-title":"Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018-2020): 19 cases","volume":"32","author":"Tracy","year":"2022","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0020","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1292\/jvms.19-0605","article-title":"Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism","volume":"82","author":"Uchida","year":"2020","journal-title":"J Vet Med Sci"},{"key":"2026020304133546800_jvim17216-bib-0021","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/vec.12466","article-title":"The use of rivaroxaban for the treatment of thrombotic complications in four dogs","volume":"26","author":"Yang","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0022","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/00498250500250493","article-title":"Pharmacokinetics of BAY 59-7939\u2014an oral, direct factor Xa inhibitor\u2014in rats and dogs","volume":"35","author":"Weinz","year":"2005","journal-title":"Xenobiotica"},{"key":"2026020304133546800_jvim17216-bib-0023","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2026020304133546800_jvim17216-bib-0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tvjl.2017.03.006","article-title":"Anticoagulant activity of oral rivaroxaban in healthy dogs","volume":"223","author":"Conversy","year":"2017","journal-title":"Vet J"},{"key":"2026020304133546800_jvim17216-bib-0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13318-011-0037-x","article-title":"Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor","volume":"36","author":"He","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026020304133546800_jvim17216-bib-0026","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","article-title":"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor","volume":"31","author":"Wong","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"2026020304133546800_jvim17216-bib-0027","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1124\/dmd.108.025981","article-title":"Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2026020304133546800_jvim17216-bib-0028","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/jsap.13560","article-title":"Regression of venous thrombus after trans-sphenoidal hypophysectomy for pituitary-dependent hyperadrenocorticism in a dog","volume":"64","author":"Tanaka","year":"2023","journal-title":"J Small Anim Pract"},{"key":"2026020304133546800_jvim17216-bib-0029","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/vms3.1210","article-title":"Secondary right atrial thrombosis in three dogs: antithrombotics therapy and echocardiographic follow-up","volume":"9","author":"Yoshida","year":"2023","journal-title":"Vet Med Sci"},{"key":"2026020304133546800_jvim17216-bib-0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/vec.12801","article-title":"American College of Veterinary Emergency and Critical Care (ACVECC) consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE) guidelines: small animal","volume":"29","author":"Goggs","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0031","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2019.05.019","article-title":"It's time for head-to-head trials with direct oral anticoagulants","volume":"180","author":"Tritschler","year":"2019","journal-title":"Thromb Res"},{"key":"2026020304133546800_jvim17216-bib-0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144856","article-title":"Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"10","author":"Cohen","year":"2015","journal-title":"PLoS One"},{"key":"2026020304133546800_jvim17216-bib-0033","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"key":"2026020304133546800_jvim17216-bib-0034","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ageing\/afx073","article-title":"Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: a case report","volume":"46","author":"Nagasayi","year":"2017","journal-title":"Age Ageing"},{"key":"2026020304133546800_jvim17216-bib-0035","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5482\/HAMO-17-01-0005","article-title":"Pulmonary embolism four days after interruption of therapy with rivaroxaban","volume":"37","author":"Gondor","year":"2017","journal-title":"Hamostaseologie"},{"key":"2026020304133546800_jvim17216-bib-0036","article-title":"Compounding Animal Drugs From Bulk Drug Substances","author":"Center for Veterinary Medicine","year":"2022"},{"key":"2026020304133546800_jvim17216-bib-0037","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2460\/ajvr.73.12.1864","article-title":"Comparison of venous sampling methods for thromboelastography in clinically normal dogs","volume":"73","author":"Walker","year":"2012","journal-title":"Am J Vet Res"},{"key":"2026020304133546800_jvim17216-bib-0038","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.aca.2019.03.061","article-title":"Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: a critical review","volume":"1076","author":"Gouveia","year":"2019","journal-title":"Anal Chim Acta"},{"key":"2026020304133546800_jvim17216-bib-0039","article-title":"ICH Harmonised Guideline: Validation of Analytical Procedures Q2(R2). Step 4 Edition","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2023"},{"key":"2026020304133546800_jvim17216-bib-0040","article-title":"General Chapter 1225: Validation of Compendial Procedures","author":"USP-NF","year":"2024"},{"key":"2026020304133546800_jvim17216-bib-0041","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/vec.12524","article-title":"Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats","volume":"26","author":"Dixon-Jimenez","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0042","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fvets.2018.00304","article-title":"Pharmacokinetics and pharmacodynamics of an oral formulation of apixaban in horses after oral and intravenous administration","volume":"5","author":"Serpa","year":"2018","journal-title":"Front Vet Sci"},{"key":"2026020304133546800_jvim17216-bib-0043","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/vec.13019","article-title":"The influence of feeding and gastroprotectant medications on the factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs","volume":"31","author":"Lynch","year":"2021","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0044","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/vms3.161","article-title":"A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs","volume":"5","author":"Evans","year":"2019","journal-title":"Vet Med Sci"},{"key":"2026020304133546800_jvim17216-bib-0045","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jvim.16572","article-title":"Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs","volume":"36","author":"Hafner","year":"2022","journal-title":"J Vet Intern Med"},{"key":"2026020304133546800_jvim17216-bib-0046","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40360-020-00414-5","article-title":"Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study","volume":"21","author":"Li","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026020304133546800_jvim17216-bib-0047","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026020304133546800_jvim17216-bib-0048","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and Apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"key":"2026020304133546800_jvim17216-bib-0049","doi-asserted-by":"crossref","first-page":"218","DOI":"10.29074\/ascls.28.4.218","article-title":"Oral factor Xa inhibitors and clinical laboratory monitoring","volume":"28","author":"White","year":"2015","journal-title":"Am Soc Clin Lab Sci"},{"key":"2026020304133546800_jvim17216-bib-0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1538-7836.2010.04098.x","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays","volume":"9","author":"Hillarp","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2026020304133546800_jvim17216-bib-0051","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jth.12649","article-title":"Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays","volume":"12","author":"Hillarp","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2026020304133546800_jvim17216-bib-0052","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jvim.15478","article-title":"Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time","volume":"33","author":"Bae","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020304133546800_jvim17216-bib-0053","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2026020304133546800_jvim17216-bib-0054","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FTD.0000000000000594","article-title":"Pharmacokinetic and pharmacodynamic drug monitoring of direct-acting oral anticoagulants: where do we stand?","volume":"41","author":"Wieland","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2026020304133546800_jvim17216-bib-0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"2026020304133546800_jvim17216-bib-0056","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cll.2014.06.005","article-title":"Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing","volume":"34","author":"Levy","year":"2014","journal-title":"Clin Lab Med"},{"key":"2026020304133546800_jvim17216-bib-0057","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/vec.13011","article-title":"Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs","volume":"31","author":"Lynch","year":"2021","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020304133546800_jvim17216-bib-0058","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.rvsc.2019.08.030","article-title":"Measurements of endogenous thrombin potential using the CAT method in cats: reference values and influence of the direct factor Xa inhibitor apixaban","volume":"127","author":"Mischke","year":"2019","journal-title":"Res Vet Sci"},{"key":"2026020304133546800_jvim17216-bib-0059","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/vcp.12489","article-title":"Effect of dalteparin administration on thrombin generation kinetics in healthy dogs","volume":"46","author":"Gara-Boivin","year":"2017","journal-title":"Vet Clin Pathol"},{"key":"2026020304133546800_jvim17216-bib-0060","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays \u2013 a review of the literature","volume":"21","author":"Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2026020304133546800_jvim17216-bib-0061","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026020304133546800_jvim17216-bib-0062","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejvs.2020.03.051","article-title":"Critical review of large animal models for central deep venous thrombosis","volume":"60","author":"Schwein","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026020304133546800_jvim17216-bib-0063","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0049-3848(00)00334-0","article-title":"Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism","volume":"100","author":"Morris","year":"2000","journal-title":"Thromb Res"},{"key":"2026020304133546800_jvim17216-bib-0064","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/iep.12040","article-title":"Evaluation of autologous blood clot subsegmental pulmonary thromboembolism in minimally invasive experimental canine model","volume":"94","author":"Kang","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"2026020304133546800_jvim17216-bib-0065","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.thromres.2015.01.016","article-title":"Establishment of a canine model of acute pulmonary embolism with definite right ventricular dysfunction through introduced autologous blood clots","volume":"135","author":"Zhao","year":"2015","journal-title":"Thromb Res"},{"key":"2026020304133546800_jvim17216-bib-0066","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and Pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026020304133546800_jvim17216-bib-0067","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"2026020304133546800_jvim17216-bib-0068","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"2026020304133546800_jvim17216-bib-0069","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jcph.288","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF","volume":"54","author":"Girgis","year":"2014","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/6\/3242\/66662110\/jvim17216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/6\/3242\/66662110\/jvim17216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:14:13Z","timestamp":1770110053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/38\/6\/3242\/8448495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.17216","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}